CSS LLC’s Intra-Cellular Therapies ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-28,904
| Closed | -$3.81M | – | 1205 |
|
|
2025
Q1 | $3.81M | Buy |
+28,904
| New | +$3.6M | 0.21% | 85 |
|
|
2023
Q1 | – | Sell |
-44,189
| Closed | -$2.34M | – | 933 |
|
|
2022
Q4 | $2.34M | Sell |
44,189
-1,066
| -2% | -$53.4K | 0.13% | 153 |
|
|
2022
Q3 | $2.11M | Sell |
45,255
-14,513
| -24% | -$758K | 0.1% | 218 |
|
|
2022
Q2 | $3.41M | Sell |
59,768
-773
| -1% | -$43.8K | 0.14% | 165 |
|
|
2022
Q1 | $3.7M | Buy |
60,541
+34,287
| +131% | +$1.78M | 0.13% | 147 |
|
|
2021
Q4 | $1.37M | Buy |
26,254
+4,682
| +22% | +$197K | 0.05% | 345 |
|
|
2021
Q3 | $804K | Buy |
21,572
+17,299
| +405% | +$601K | 0.03% | 482 |
|
|
2021
Q2 | $174K | Sell |
4,273
-26,515
| -86% | -$980K | 0.01% | 868 |
|
|
2021
Q1 | $1.04M | Sell |
30,788
-18,800
| -38% | -$652K | 0.04% | 374 |
|
|
2020
Q4 | $1.58M | Sell |
49,588
-15,398
| -24% | -$405K | 0.06% | 239 |
|
|
2020
Q3 | $1.67M | Buy |
64,986
+39,101
| +151% | +$892K | 0.08% | 208 |
|
|
2020
Q2 | $664K | Buy |
25,885
+2,303
| +10% | +$46.6K | 0.04% | 335 |
|
|
2020
Q1 | $362K | Buy |
23,582
+11,957
| +103% | +$260K | 0.03% | 349 |
|
|
2019
Q4 | $399K | Buy |
+11,625
| New | +$140K | 0.02% | 392 |
|
Other funds holding ITCI
CSS LLC's ITCI Position: Q2 2025 in Review
CSS LLC sold out of Intra-Cellular Therapies (ITCI) in Q2 2025, closing a stake of 28,904 shares — an estimated $3.81M sold.
CSS LLC first reported a position in ITCI in Q4 2019 and held it in 14 quarters. The position peaked at $3.81M in Q1 2025. 2 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- CSS LLC reported no remaining Intra-Cellular Therapies position as of Q2 2025 after selling out during the quarter.
- CSS LLC sold 28,904 Intra-Cellular Therapies shares in Q2 2025, an estimated $3.81M.
- CSS LLC first reported a position in Intra-Cellular Therapies in Q4 2019 and held it in 14 quarters.
- CSS LLC's Intra-Cellular Therapies position peaked at $3.81M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Intra-Cellular Therapies as of Q2 2025.
Based on CSS LLC's 13F filing for Q2 2025, filed 14 Aug 2025.